Quantcast
Last updated on April 20, 2014 at 17:20 EDT

The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical’s ALFApump® System

November 4, 2011

ZURICH, Switzerland, November 4, 2011 /PRNewswire/ –

Major milestone achieved in the commercial launch of new technology in
the treatment of patients with refractory ascites due to liver cirrhosis.

Sequana Medical, the Medical University of Vienna and Vienna General
Hospital (AKH Wien) reported that the first two commercial implants
worldwide of the ALFApump System were performed at Vienna General Hospital
in October, under the supervision of Univ. Prof. Dr. Markus
Peck-Radosavljevic, Vice-Chairman, Division of Gastroenterology and
Hepatology (Chairman: Prof. Dr. M. Trauner), Dept. of Internal Medicine III.
Vienna General Hospital is one of Europe’s largest teaching hospitals. The
ALFApump System is indicated for the management of refractory and recurrent
ascites due to liver cirrhosis, a condition where massive and uncontrolled
fluid accumulation occurs in the abdominal cavity.

“I believe that the ALFApump System represents a real breakthrough in
the treatment of refractory ascites. By using the ALFApump, the patient no
longer has to return to the hospital on a frequent basis to undergo drainage
procedures. This positively impacts on both Quality of Life of the patient
and the financial burden to the healthcare system. The implant procedure for
both patients went smoothly and without complications”, commented Professor
Peck-Radosavljevic.

Refractory ascites occurs when patients with ascites no longer respond
to medical therapy. This condition affects over 100,000 patients in Europe
and the US every year. The number of patients suffering from ascites is
growing at approximately 10% a year due to the accelerating incidence of
hepatitis- and obesity-related liver disease. The primary treatment for
ascites is paracentesis, a procedure in which a large bore needle is
inserted into the patient’s abdomen to remove between 5-10 litres of ascites
that has accumulated over a period of a week or two. The cumulative cost of
ascites-related care for these patients often exceeds EUR40,000 each year.

The ALFApump System consists of a subcutaneously implanted
battery-powered pump with a catheter placed in the abdominal cavity and
another catheter connected to the bladder. The ALFApump System automatically
and continually collects fluid as it forms in the abdominal cavity and moves
it to the bladder, where it is eliminated through normal urination. The
ALFApump is recharged wirelessly and can be programmed to meet the unique
needs of each patient.

“We are delighted to be partnering with Professor Peck-Radosavljevic,
the Medical University of Vienna and the Vienna General Hospital team”,
stated Dan Rose, Vice President of Commercial Operations. “The ALFApump
System is designed to offer patients better clinical outcomes and quality of
life while eliminating the requirement for repeated expensive and burdensome
invasive procedures.”

About Sequana Medical:

Sequana Medical is a Swiss medical device company dedicated to improving
patient lives through innovative technologies to manage fluid within the
body.

        Contact:
        Sequana Medical
        Emily Woodward
        Product Marketing Manager
        Emily.woodward@sequanamedical.com
        Tel: +41-44-446-50-74

SOURCE Sequana Medical AG


Source: PR Newswire